IVIG in BK Nephropathy
IVIG can be considered as a second-line adjunctive therapy for biopsy-proven BK virus nephropathy that persists despite maximal immunosuppression reduction, though it is not a first-line treatment and lacks strong guideline support. 1, 2
Primary Management: Immunosuppression Reduction First
Reduction of immunosuppressive medications remains the only intervention with established efficacy and must be the initial approach. 1, 2 The American Society of Transplantation recommends reducing immunosuppression when plasma BK viral load persistently exceeds 10,000 copies/mL. 3, 1 This typically involves:
- Reducing or discontinuing antimetabolites (mycophenolate mofetil or azathioprine) first 1
- Gradual reduction with close monitoring to avoid precipitous acute rejection 1
- Continuing reduction until viral load decreases 3, 1
When to Consider IVIG
IVIG should only be considered after 8 weeks of inadequate response to immunosuppression reduction and leflunomide therapy in patients with:
- Persistent BK viremia (>10,000 copies/mL) despite maximal immunosuppression reduction 4, 5
- Biopsy-proven BK virus nephropathy with progressive allograft dysfunction 1, 2
- Rising or persistently elevated viral loads despite first-line management 4, 6
IVIG Dosing Protocol
The recommended dose is 2 g/kg administered intravenously as a single infusion. 6, 5 Based on available evidence:
- Administer 2 g/kg as a single dose initially 6, 5
- May repeat dosing if viremia persists or recurs (typically at intervals of several months based on viral load response) 6
- Monitor BK viral load weekly initially, then monthly after treatment 4, 7
Evidence Supporting IVIG Use
The evidence for IVIG in BK nephropathy consists primarily of case series and reports, not randomized trials. 6 Key findings include:
- In a series of 30 patients with persistent BK viremia despite standard therapy, 90% cleared viremia after IVIG with 96.7% graft survival at 12 months 4
- Pediatric case series showed successful viral clearance and histological resolution of nephropathy with 2 g/kg dosing 5
- Retrospective analysis of 86 patients showed IVIG significantly lowered viral load in responders (median 1,369 copies/mL at 6 months vs 12,789 copies/mL in non-responders) 7
However, baseline viral load predicts response: patients with very high viral loads at diagnosis (>200,000 copies/mL) respond less favorably than those with lower loads (<30,000 copies/mL). 7
Critical Pitfalls and Contraindications
Do not use IVIG as first-line therapy or before adequate immunosuppression reduction. 1, 2 One case report documented exponential increase in BK viremia and progression to overt nephropathy following IVIG administration for acute cellular rejection without immunosuppression reduction. 8 This highlights that:
- IVIG may worsen BK infection if given without concurrent immunosuppression reduction 8
- Coexistent acute rejection complicates management and requires careful biopsy interpretation 8
- Acute rejection occurs in 59-79% of patients after immunosuppression reduction and must be differentiated from BKVN progression 2
Monitor closely for volume overload, headache, chills, rigors, fever, and myalgia during IVIG infusion. 9 Ensure adequate renal function assessment before dosing given the high protein load. 9
Monitoring After IVIG
- Measure plasma BK viral load weekly for the first month, then monthly 4, 7
- Monitor serum creatinine and allograft function closely 2, 6
- Consider repeat biopsy if renal function deteriorates despite viral load reduction 2
- Continue surveillance for at least 12 months as viral rebound can occur 4, 6
Alternative Adjunctive Therapies
If IVIG is ineffective or contraindicated, consider: